190 related articles for article (PubMed ID: 36145630)
1. Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections.
Stroffolini G; De Nicolò A; Gaviraghi A; Mula J; Cariti G; Scabini S; Manca A; Cusato J; Corcione S; Bonora S; Di Perri G; De Rosa FG; D'Avolio A
Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145630
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context.
De Nicolò A; Stroffolini G; Antonucci M; Mula J; De Vivo ED; Cusato J; Palermiti A; Cariti G; Di Perri G; Corcione S; De Rosa FG; D'Avolio A
Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680409
[TBL] [Abstract][Full Text] [Related]
3. Dalbavancin in Bone and Joint Infections: A Systematic Review.
Lovatti S; Tiecco G; Mulé A; Rossi L; Sforza A; Salvi M; Signorini L; Castelli F; Quiros-Roldan E
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513919
[TBL] [Abstract][Full Text] [Related]
4. Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years.
Salinas-Botrán A; Olmos-Blanco C; Fernández de Velasco-Pérez D; Guzmán-Carreras A; Morales-Rosas A; Gómez-Ramírez D
Enferm Infecc Microbiol Clin (Engl Ed); 2024 May; ():. PubMed ID: 38763866
[TBL] [Abstract][Full Text] [Related]
5. A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections.
Gatti M; Viale P; Cojutti PG; Zamparini E; De Paolis M; Giannella M; Pea F; Tedeschi S
Int J Antimicrob Agents; 2023 May; 61(5):106773. PubMed ID: 36878410
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience.
Cattaneo D; Fusi M; Colaneri M; Fusetti C; Genovese C; Giorgi R; Matone M; Merli S; Petri F; Gori A
Antibiotics (Basel); 2023 Dec; 13(1):. PubMed ID: 38247579
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections.
Cojutti PG; Rinaldi M; Zamparini E; Rossi N; Tedeschi S; Conti M; Pea F; Viale P
Antimicrob Agents Chemother; 2023 May; 65(5):. PubMed ID: 33649108
[No Abstract] [Full Text] [Related]
8. Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections.
Barone R; Conti M; Cojutti PG; Gatti M; Viale P; Pea F
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839804
[TBL] [Abstract][Full Text] [Related]
9. Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing.
Caselli D; Mariani M; Colomba C; Ferrecchi C; Cafagno C; Trotta D; Carloni I; Dibello D; Castagnola E; Aricò M
Children (Basel); 2024 Jan; 11(1):. PubMed ID: 38255391
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age.
Bradley JS; Puttagunta S; Rubino CM; Blumer JL; Dunne M; Sullivan JE
Pediatr Infect Dis J; 2015 Jul; 34(7):748-52. PubMed ID: 25551831
[TBL] [Abstract][Full Text] [Related]
11. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
[TBL] [Abstract][Full Text] [Related]
12. Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.
Smith JR; Roberts KD; Rybak MJ
Infect Dis Ther; 2015 Sep; 4(3):245-58. PubMed ID: 26341488
[TBL] [Abstract][Full Text] [Related]
13. Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.
Poliseno M; Bavaro DF; Brindicci G; Luzzi G; Carretta DM; Spinarelli A; Messina R; Miolla MP; Achille TI; Dibartolomeo MR; Dell'Aera M; Saracino A; Angarano G; Favale S; D'Agostino C; Moretti B; Signorelli F; Taglietti C; Carbonara S
Clin Drug Investig; 2021 May; 41(5):437-448. PubMed ID: 33884583
[TBL] [Abstract][Full Text] [Related]
14. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
Gatti M; Andreoni M; Pea F; Viale P
Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
[TBL] [Abstract][Full Text] [Related]
15. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
[TBL] [Abstract][Full Text] [Related]
16. In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry.
Esposito S; Pagliano P; De Simone G; Guarino A; Pan A; Brambilla P; Mastroianni C; Lichtner M; Brugnaro P; Carretta A; Santantonio T; Brindicci G; Carrega G; Montagnani F; Lapadula G; Spolti A; Luzzati R; Schiaroli E; Scaglione V; Pallotto C; Tacconi D; Quintieri F; Trecarichi E;
Infection; 2024 Feb; ():. PubMed ID: 38324144
[TBL] [Abstract][Full Text] [Related]
17. Dalbavancin in clinical practice in Spain: a 2 year retrospective study.
Morata L; Aguado JM; Salavert M; Pasquau J; Míguez E; Muñoz P; Rosselló I; Almirante B
JAC Antimicrob Resist; 2022 Dec; 4(6):dlac120. PubMed ID: 36570687
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
[TBL] [Abstract][Full Text] [Related]
19. Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA.
Riccobono E; Giani T; Baldi G; Arcangeli S; Antonelli A; Tellone V; Del Vecchio A; De Joannon AC; Rossolini GM
Int J Antimicrob Agents; 2022 Feb; 59(2):106503. PubMed ID: 34929289
[TBL] [Abstract][Full Text] [Related]
20. Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center.
Brescini L; Della Martera F; Morroni G; Mazzanti S; Di Pietrantonio M; Mantini P; Candelaresi B; Pallotta F; Olivieri S; Iencinella V; Castelletti S; Cocci E; Polo RG; Veccia S; Cirioni O; Tavio M; Giacometti A
Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
